Myrexis discontinues Azixa

Myrexis Inc. (NASDAQ:MYRX) said it will discontinue development of Azixa verubulin, a small molecule microtubule destabilizing apoptosis-inducer in Phase IIb testing for glioblastoma multiforme (GBM). According to the company, completing the Phase IIb trial would require a "disproportionate investment of time and resources relative to its likelihood of technical and regulatory success." Myrexis has exclusive rights to Azixa from EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT ). EpiCept, which declined to comment, was off $0.01 to $0.40 on Friday. Myrexis was up $0.03 to $2.86. ...